{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:54:22Z","timestamp":1785459262243,"version":"3.56.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s15010-021-01730-6","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T06:02:27Z","timestamp":1639375347000},"page":"295-308","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection"],"prefix":"10.1007","volume":"50","author":[{"given":"Mostafa","family":"Akbarzadeh-Khiavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Torabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4180-8028","authenticated-orcid":false,"given":"Leila","family":"Rahbarnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8997-2003","authenticated-orcid":false,"given":"Azam","family":"Safary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"1730_CR1","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1002\/hed.26204","volume":"42","author":"LA Vaira","year":"2020","unstructured":"Vaira LA, et al. Objective evaluation of anosmia and ageusia in COVID-19 patients: single-center experience on 72 cases. Head Neck. 2020;42:1252\u20138.","journal-title":"Head Neck"},{"key":"1730_CR2","doi-asserted-by":"publisher","first-page":"e0248009","DOI":"10.1371\/journal.pone.0248009","volume":"16","author":"A De Vito","year":"2021","unstructured":"De Vito A, et al. Predictors of infection, symptoms development, and mortality in people with SARS-CoV-2 living in retirement nursing homes. PLoS ONE. 2021;16:e0248009.","journal-title":"PLoS ONE"},{"key":"1730_CR3","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1097\/IPC.0000000000000952","volume":"28","author":"N Geremia","year":"2020","unstructured":"Geremia N, et al. A case of vasculitis-like skin eruption associated with COVID-19. Infect Dis Clin Pract. 2020;28:e30\u20131.","journal-title":"Infect Dis Clin Pract"},{"key":"1730_CR4","first-page":"e304","volume":"61","author":"Y Alimohamadi","year":"2020","unstructured":"Alimohamadi Y, et al. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020;61:e304\u201312.","journal-title":"J Prev Med Hyg"},{"key":"1730_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239\u201342.","journal-title":"JAMA"},{"key":"1730_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/ph14040332","volume":"14","author":"T Ginex","year":"2021","unstructured":"Ginex T, et al. Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico\/in vitro screening methods. Pharmaceuticals. 2021;14:332.","journal-title":"Pharmaceuticals"},{"key":"1730_CR7","doi-asserted-by":"crossref","unstructured":"Chow NF-DK, Gierke R, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019\u2014United States. MMWR Morb Mortal Wkly Rep 2020;69:382\u20136","DOI":"10.15585\/mmwr.mm6913e2"},{"key":"1730_CR8","first-page":"7861","volume":"24","author":"A De Vito","year":"2020","unstructured":"De Vito A, et al. Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia Italy. Eur Rev Med Pharmacol Sci. 2020;24:7861\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1730_CR9","first-page":"2435","volume":"25","author":"RN Dallocchio","year":"2021","unstructured":"Dallocchio RN, et al. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19. Eur Rev Med Pharmacol Sci. 2021;25:2435\u201348.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1730_CR10","doi-asserted-by":"crossref","unstructured":"Hossen MS, et al. A review on current repurposing drugs for the treatment of COVID-19: reality and challenges. SN Compr Clin Med 2020; 1\u201313","DOI":"10.1007\/s42399-020-00485-9"},{"key":"1730_CR11","doi-asserted-by":"crossref","unstructured":"Saber-Ayad M, Saleh MA, Abu-Gharbieh E. The rationale for potential pharmacotherapy of COVID-19. Pharmaceuticals (Basel) 2020;13","DOI":"10.3390\/ph13050096"},{"key":"1730_CR12","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12931-020-01479-w","volume":"21","author":"Z Zhu","year":"2020","unstructured":"Zhu Z, et al. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res. 2020;21:224.","journal-title":"Respir Res"},{"key":"1730_CR13","doi-asserted-by":"crossref","unstructured":"Santos J, et al. Repurposing therapeutics for potential treatment of SARS-CoV-2: a review. Viruses 2020;12","DOI":"10.3390\/v12070705"},{"key":"1730_CR14","first-page":"64","volume":"20","author":"MA Martinez","year":"2020","unstructured":"Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;20:64.","journal-title":"Antimicrob Agents Chemother"},{"key":"1730_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","volume":"384","author":"AC Kalil","year":"2021","unstructured":"Kalil AC, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795\u2013807.","journal-title":"N Engl J Med"},{"key":"1730_CR16","unstructured":"Coronavirus (COVID-19) Update: FDA authorizes drug combination for treatment of COVID-19. 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19. (Accessed date 19 Nov 2020)"},{"key":"1730_CR17","unstructured":"Baricitinib EUA Letter of authorization. 2021. https:\/\/www.fda.gov\/media\/143822\/download. (Accessed 28 Jul 2021)"},{"key":"1730_CR18","unstructured":"Lilly E. Fact sheet for healthcare providers: emergency use authorization (EUA) of baricitinib. 2021. https:\/\/www.fda.gov\/media\/143823\/download. (Accessed date Aug 2021)"},{"key":"1730_CR19","doi-asserted-by":"crossref","unstructured":"Calabrese C, et al. Practical aspects of targeting IL-6 in COVID-19 disease. Cleve Clin J Med 2020","DOI":"10.3949\/ccjm.87a.ccc018"},{"key":"1730_CR20","doi-asserted-by":"crossref","unstructured":"Calabrese LH, Calabrese C. Baricitinib and dexamethasone for hospitalized patients with COVID-19. Cleve Clin J Med 2021","DOI":"10.3949\/ccjm.88a.ccc073"},{"key":"1730_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3949\/ccjm.87a.ccc008","volume":"87","author":"LH Calabrese","year":"2020","unstructured":"Calabrese LH. Cytokine storm and the prospects for immunotherapy with COVID-19. Cleve Clin J Med. 2020;87:389\u201393.","journal-title":"Cleve Clin J Med"},{"key":"1730_CR22","unstructured":"Beigel JH, et al. Remdesivir for the treatment of Covid-19\u2014preliminary report. N Engl J Med 2020"},{"key":"1730_CR23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1055\/a-1347-6070","volume":"121","author":"A Di Castelnuovo","year":"2021","unstructured":"Di Castelnuovo A, et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study. Thromb Haemost. 2021;121:1054\u201365.","journal-title":"Thromb Haemost"},{"key":"1730_CR24","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1111\/febs.15369","volume":"287","author":"OO Glebov","year":"2020","unstructured":"Glebov OO. Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing. FEBS J. 2020;287:3664\u201371.","journal-title":"FEBS J"},{"key":"1730_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12967-020-02344-6","volume":"18","author":"M Pachetti","year":"2020","unstructured":"Pachetti M, et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. 2020;18:179.","journal-title":"J Transl Med"},{"key":"1730_CR26","doi-asserted-by":"crossref","unstructured":"Mazzon M, Marsh M. Targeting viral entry as a strategy for broad-spectrum antivirals. F1000Res 2019; 8","DOI":"10.12688\/f1000research.19694.1"},{"key":"1730_CR27","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, et al. Remdesivir for the treatment of Covid-19. N Engl J Med. 2020;383:1813\u201326.","journal-title":"N Engl J Med"},{"key":"1730_CR28","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/phar.2398","volume":"40","author":"A Barlow","year":"2020","unstructured":"Barlow A, et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. 2020;40:416\u201337.","journal-title":"Pharmacotherapy"},{"key":"1730_CR29","unstructured":"Cao B, et al. A trial of lopinavir\u2013ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020"},{"key":"1730_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497\u2013506.","journal-title":"China Lancet"},{"key":"1730_CR31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cegh.2020.07.006","volume":"9","author":"A Frediansyah","year":"2021","unstructured":"Frediansyah A, et al. Antivirals for COVID-19: a critical review. Clin Epidemiol Glob Health. 2021;9:90\u20138.","journal-title":"Clin Epidemiol Glob Health"},{"key":"1730_CR32","doi-asserted-by":"crossref","unstructured":"Magro G. SARS-CoV-2 and COVID-19: what are our options? Where should we focus our attention on to find new drugs and strategies? Travel Med Infect Dis 2020;37: 101685","DOI":"10.1016\/j.tmaid.2020.101685"},{"key":"1730_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11010-020-03924-2","volume":"476","author":"P Kumar","year":"2021","unstructured":"Kumar P, et al. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. Mol Cell Biochem. 2021;476:553\u201374.","journal-title":"Mol Cell Biochem"},{"key":"1730_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s15010-020-01476-7","volume":"48","author":"A Cingolani","year":"2020","unstructured":"Cingolani A, et al. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab. Infection. 2020;48:767\u201371.","journal-title":"Infection"},{"key":"1730_CR35","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3892\/ijmm.2020.4608","volume":"46","author":"GM Nitulescu","year":"2020","unstructured":"Nitulescu GM, et al. Comprehensive analysis of drugs to treat SARS-CoV-2 infection: mechanistic insights into current COVID-19 therapies (Review). Int J Mol Med. 2020;46:467\u201388.","journal-title":"Int J Mol Med"},{"key":"1730_CR36","first-page":"1","volume":"419","author":"AH de Wilde","year":"2018","unstructured":"de Wilde AH, et al. Host factors in coronavirus replication. Curr Top Microbiol Immunol. 2018;419:1\u201342.","journal-title":"Curr Top Microbiol Immunol"},{"key":"1730_CR37","first-page":"523","volume":"25","author":"A De Vito","year":"2021","unstructured":"De Vito A, et al. Does angiotensin II receptor blockers increase the risk of SARS-CoV-2 infection? A real-life experience. Eur Rev Med Pharmacol Sci. 2021;25:523\u20136.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1730_CR38","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671\u201381.","journal-title":"Circ Res"},{"key":"1730_CR39","doi-asserted-by":"crossref","unstructured":"Lotfi F, et al. Micronutrient therapy and effective immune response: a promising approach for management of COVID-19. Infection 2021; 1\u201315","DOI":"10.1007\/s15010-021-01644-3"},{"key":"1730_CR40","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/35099560","volume":"413","author":"L Alexopoulou","year":"2001","unstructured":"Alexopoulou L, et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413:732\u20138.","journal-title":"Nature"},{"key":"1730_CR41","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1146\/annurev-immunol-032713-120156","volume":"32","author":"J Wu","year":"2014","unstructured":"Wu J, Chen ZJ. Innate immune sensing and signaling of cytosolic nucleic acids. Annu Rev Immunol. 2014;32:461\u201388.","journal-title":"Annu Rev Immunol"},{"key":"1730_CR42","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1126\/science.1229963","volume":"339","author":"J Wu","year":"2013","unstructured":"Wu J, et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science. 2013;339:826\u201330.","journal-title":"Science"},{"key":"1730_CR43","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.cell.2005.08.012","volume":"122","author":"RB Seth","year":"2005","unstructured":"Seth RB, et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-\u03baB and IRF3. Cell. 2005;122:669\u201382.","journal-title":"Cell"},{"issue":"4","key":"1730_CR44","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1152\/advan.00058.2013","volume":"37","author":"R Suresh","year":"2013","unstructured":"Suresh R, Mosser DM. Pattern recognition receptors in innate immunity, host defense, and immunopathology. Adv Physiol Educ. 2013;37(4):284\u201391.","journal-title":"Adv Physiol Educ"},{"key":"1730_CR45","doi-asserted-by":"crossref","unstructured":"Harrison DA. The Jak\/STAT pathway. Cold Spring Harb Perspect Biol 2012;4.","DOI":"10.1101\/cshperspect.a011205"},{"key":"1730_CR46","doi-asserted-by":"crossref","unstructured":"Satarker S, et al. JAK-STAT pathway inhibition and their implications in COVID-19 Therapy. Postgrad Med 2020; 1\u201319","DOI":"10.1080\/00325481.2020.1855921"},{"key":"1730_CR47","doi-asserted-by":"publisher","first-page":"8671","DOI":"10.1007\/s13277-015-3534-8","volume":"36","author":"HX Li","year":"2015","unstructured":"Li HX, et al. Retinoic acid amide inhibits JAK\/STAT pathway in lung cancer which leads to apoptosis. Tumour Biol. 2015;36:8671\u20138.","journal-title":"Tumour Biol"},{"key":"1730_CR48","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4049\/jimmunol.178.1.280","volume":"178","author":"MA Burchill","year":"2007","unstructured":"Burchill MA, et al. IL-2 receptor \u03b2-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol. 2007;178:280\u201390.","journal-title":"J Immunol"},{"key":"1730_CR49","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798\u2013809.","journal-title":"Nat Rev Cancer"},{"key":"1730_CR50","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.tcb.2008.08.008","volume":"18","author":"WX Li","year":"2008","unstructured":"Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol. 2008;18:545\u201351.","journal-title":"Trends Cell Biol"},{"key":"1730_CR51","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","volume":"66","author":"JJ O'Shea","year":"2015","unstructured":"O\u2019Shea JJ, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311\u201328.","journal-title":"Annu Rev Med"},{"key":"1730_CR52","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","volume":"41","author":"Y Huang","year":"2020","unstructured":"Huang Y, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41:1141\u20139.","journal-title":"Acta Pharmacol Sin"},{"key":"1730_CR53","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16:843.","journal-title":"Nat Rev Drug Discov"},{"key":"1730_CR54","doi-asserted-by":"publisher","first-page":"e28087","DOI":"10.4161\/jkst.28087","volume":"3","author":"FD B\u00f6hmer","year":"2014","unstructured":"B\u00f6hmer FD, Friedrich K. Protein tyrosine phosphatases as wardens of STAT signaling. Jak-stat. 2014;3:e28087.","journal-title":"Jak-stat"},{"key":"1730_CR55","doi-asserted-by":"publisher","first-page":"e26090","DOI":"10.4161\/jkst.26090","volume":"2","author":"L Silver-Morse","year":"2013","unstructured":"Silver-Morse L, Li WX. JAK-STAT in heterochromatin and genome stability. Jak-stat. 2013;2:e26090.","journal-title":"Jak-stat"},{"key":"1730_CR56","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.tips.2020.06.007","volume":"41","author":"W Luo","year":"2020","unstructured":"Luo W, et al. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacol Sci. 2020;41:531\u201343.","journal-title":"Trends Pharmacol Sci"},{"key":"1730_CR57","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, et al. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25.","journal-title":"Nat Rev Rheumatol"},{"key":"1730_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1\u201326.","journal-title":"Arthritis Rheumatol"},{"key":"1730_CR59","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/phar.2438","volume":"40","author":"SCJ Jorgensen","year":"2020","unstructured":"Jorgensen SCJ, et al. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy. 2020;40:843\u201356.","journal-title":"Pharmacotherapy"},{"key":"1730_CR60","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1177\/1060028019839650","volume":"53","author":"A Mogul","year":"2019","unstructured":"Mogul A, Corsi K, McAuliffe L. Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother. 2019;53:947\u201353.","journal-title":"Ann Pharmacother"},{"key":"1730_CR61","doi-asserted-by":"publisher","first-page":"21415","DOI":"10.1038\/s41598-020-78402-2","volume":"10","author":"W Wruck","year":"2020","unstructured":"Wruck W, Adjaye J. SARS-CoV-2 receptor ACE2 is co-expressed with genes related to transmembrane serine proteases, viral entry, immunity and cellular stress. Sci Rep. 2020;10:21415.","journal-title":"Sci Rep"},{"key":"1730_CR62","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson P, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30\u20131.","journal-title":"Lancet"},{"key":"1730_CR63","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","volume":"181","author":"CGK Ziegler","year":"2020","unstructured":"Ziegler CGK, et al. SARS-CoV-2 receptor ACE2 Is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell. 2020;181:1016-1035.e19.","journal-title":"Cell"},{"key":"1730_CR64","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1186\/s13063-020-04535-4","volume":"21","author":"S Kulkarni","year":"2020","unstructured":"Kulkarni S, et al. Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients - mulTi-Arm therapeutic study in pre-ICu patients admitted with Covid-19 - Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:626.","journal-title":"Trials"},{"key":"1730_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13063-021-05072-4","volume":"22","author":"G Moreno-Gonz\u00e1lez","year":"2021","unstructured":"Moreno-Gonz\u00e1lez G, et al. A Phase I\/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2021;22:1\u20134.","journal-title":"Trials"},{"key":"1730_CR66","doi-asserted-by":"crossref","unstructured":"Patoulias D, et al. Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clin Rheumatol, 2021; 1\u20134","DOI":"10.1007\/s10067-021-05884-4"},{"key":"1730_CR67","doi-asserted-by":"publisher","first-page":"108027","DOI":"10.1016\/j.intimp.2021.108027","volume":"99","author":"CY Chen","year":"2021","unstructured":"Chen CY, et al. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2021;99:108027.","journal-title":"Int Immunopharmacol"},{"key":"1730_CR68","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1172\/JCI141772","volume":"130","author":"V Bronte","year":"2020","unstructured":"Bronte V, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130:6409\u201316.","journal-title":"J Clin Invest"},{"key":"1730_CR69","doi-asserted-by":"crossref","unstructured":"Iglesias GR, et al. Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients. Eur J Hosp Pharm 2021.","DOI":"10.1136\/ejhpharm-2021-002741"},{"key":"1730_CR70","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/cid\/ciaa879","volume":"72","author":"BK Titanji","year":"2021","unstructured":"Titanji BK, et al. Use of baricitinib in patients with moderate to severe coronavirus disease 2019. Clin infect Dis Official Pub Infect Diseases Soc Am. 2021;72:1247\u201350.","journal-title":"Clin infect Dis Official Pub Infect Diseases Soc Am"},{"key":"1730_CR71","first-page":"101115","volume":"31","author":"P Sodani","year":"2020","unstructured":"Sodani P, et al. Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis. Respir Med Case Rep. 2020;31:101115.","journal-title":"Respir Med Case Rep"},{"key":"1730_CR72","doi-asserted-by":"crossref","unstructured":"Izumo T, et al. Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19. Respir Investig 2021","DOI":"10.1016\/j.resinv.2021.07.004"},{"key":"1730_CR73","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1093\/rheumatology\/keaa587","volume":"60","author":"JL Rodriguez-Garcia","year":"2021","unstructured":"Rodriguez-Garcia JL, et al. Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study. Rheumatology. 2021;60:399\u2013407.","journal-title":"Rheumatology"},{"key":"1730_CR74","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1136\/annrheumdis-2020-219725","volume":"80","author":"A Alunno","year":"2021","unstructured":"Alunno A, et al. Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. Ann Rheum Dis. 2021;80:803\u201315.","journal-title":"Ann Rheum Dis"},{"key":"1730_CR75","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejca.2021.01.033","volume":"147","author":"N Giesen","year":"2021","unstructured":"Giesen N, et al. 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. Eur J Cancer. 2021;147:154\u201360.","journal-title":"Eur J Cancer"},{"key":"1730_CR76","doi-asserted-by":"publisher","first-page":"e04459","DOI":"10.1002\/ccr3.4459","volume":"9","author":"N Oda","year":"2021","unstructured":"Oda N, et al. Successful treatment of critical coronavirus disease 2019 in a patient with lung cancer concomitant with pembrolizumab-induced arthritis by methylprednisolone, baricitinib, and remdesivir. Clin Case Rep. 2021;9:e04459.","journal-title":"Clin Case Rep"},{"key":"1730_CR77","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng L, et al. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020;19:1505\u201311.","journal-title":"Expert Opin Drug Saf"},{"key":"1730_CR78","unstructured":"Assadiasl S, et al. Baricitinib: from rheumatoid arthritis to COVID\u2010195. J Clin Pharmacol 2021."},{"key":"1730_CR79","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1080\/14740338.2020.1774550","volume":"19","author":"F Cantini","year":"2020","unstructured":"Cantini F, et al. Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. Expert Opin Drug Saf. 2020;19:861\u201372.","journal-title":"Expert Opin Drug Saf"},{"key":"1730_CR80","doi-asserted-by":"crossref","unstructured":"Hsu JY, et al. Pharmacology and adverse events of emergency-use authorized medication in moderate to severe COVID-19. Pharmaceuticals (Basel) 2021;14.","DOI":"10.3390\/ph14100955"},{"key":"1730_CR81","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jinf.2020.04.017","volume":"81","author":"F Cantini","year":"2020","unstructured":"Cantini F, et al. Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact. J Infect. 2020;81:318\u201356.","journal-title":"J Infect"},{"key":"1730_CR82","unstructured":"Kalil AC, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med 2020"},{"key":"1730_CR83","doi-asserted-by":"crossref","unstructured":"Bhimraj A, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Gallagher J, Muller WJ, O'Horo JC, Shoham S, Murad MH, Mustafa RA, Sultan S, Falck-Ytter Y. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. 2021; 5.5.1. https:\/\/www.idsociety.org\/practice-guideline\/covid-19-guideline-treatment-and-management\/. (Accessed date 21 Apr 2020)","DOI":"10.1093\/cid\/ciaa478"},{"key":"1730_CR84","doi-asserted-by":"crossref","unstructured":"Favalli EG, et al. COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 2020;19(5): 102523","DOI":"10.1016\/j.autrev.2020.102523"},{"key":"1730_CR85","doi-asserted-by":"crossref","unstructured":"Fleming SB. Viral Inhibition of the IFN-Induced JAK\/STAT signalling pathway: development of live attenuated vaccines by mutation of viral-encoded IFN-antagonists. Vaccines, 2016;4","DOI":"10.3390\/vaccines4030023"},{"key":"1730_CR86","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1172\/JCI126363","volume":"129","author":"R Channappanavar","year":"2019","unstructured":"Channappanavar R, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;129:3625\u201339.","journal-title":"J Clin Invest"},{"key":"1730_CR87","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033\u20134.","journal-title":"Lancet"},{"key":"1730_CR88","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1208\/s12248-020-00532-2","volume":"23","author":"J Majumder","year":"2021","unstructured":"Majumder J, Minko T. Recent developments on therapeutic and diagnostic approaches for COVID-19. AAPS J. 2021;23:14.","journal-title":"AAPS J"},{"key":"1730_CR89","unstructured":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 2021; 397: 1637\u201345"},{"key":"1730_CR90","first-page":"Cd14962","volume":"8","author":"K Ansems","year":"2021","unstructured":"Ansems K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021;8:Cd14962.","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-021-01730-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-021-01730-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-021-01730-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T01:48:13Z","timestamp":1676080093000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-021-01730-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1730"],"URL":"https:\/\/doi.org\/10.1007\/s15010-021-01730-6","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]},"assertion":[{"value":"21 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors gave consent for the submission and publication of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}